Is intravenous recombinant tissue plasminogen activator (rt-PA) safe for use in patients over 80 years old with acute ischaemic stroke? - The Calgary experience.
about
Outcomes of intravenous tissue plasminogen activator for acute ischemic stroke in patients aged 90 years or olderThe exact science of stroke thrombolysis and the quiet art of patient selectionThrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study.Safety of thrombolysis in patients over the age of 80Prestroke dementia is associated with poor outcomes after reperfusion therapy among elderly stroke patients.Recruitment of Ischemic Stroke Patients in Clinical trials in General Practice and Implications for Generalizability of Results.The impact of intravenous thrombolysis on outcome of patients with acute ischemic stroke after 90 years old.Thrombolysis for acute stroke with special emphasis on the very old: experience from a single Dutch centreImpact of acute ischemic stroke treatment in patients >80 years of age: the specialized program of translational research in acute stroke (SPOTRIAS) consortium experience.Thrombolysis in patients older than 80 years with acute ischaemic stroke: Canadian Alteplase for Stroke Effectiveness Study.Thrombolytic therapy for acute ischaemic stroke in octogenarians: selection by magnetic resonance imaging improves safety but does not improve outcome.Effectiveness of alteplase in the very elderly after acute ischemic strokeEfficacy of thrombolytic (rt-PA) therapy in old stroke patients: the Perugia Stroke Unit experience.Intravenous thrombolysis in patients aged more than 80 years in the three rural hospitals in southeast Poland: an observational study.Procedural predictors of outcome in patients undergoing endovascular therapy for acute ischemic stroke.Intra-arterial thrombolysis for acute ischemic stroke in octogenarians.
P2860
Q24646395-74E2955F-B0C4-4ED4-8053-A61634AC835DQ27011873-118DA92A-B6C8-45B0-8552-ECD6CE9B6F4CQ33938946-283B3153-54F6-4EE0-B77F-B9A1264BF7B0Q35799271-C2A64F87-5DD5-42C8-BBFD-A13A7B3AE6BCQ35848283-918903C3-4087-42EC-AB1E-1A955154B37BQ36048616-7146A095-6C18-4362-9E44-48E9ADA2E291Q36113608-0B827A42-6E9E-41C9-9840-46B8D25A34A3Q36143040-F19E0383-7CD2-4880-A26D-34FD0C8B3B69Q36195506-0D5D8044-86DC-4EBD-A361-C7098BA1CED9Q36226503-8BFEEF98-2C69-4F9F-9F6A-4035411D13AEQ36227021-C24645A5-14B7-41E8-A75C-ED8443C0FDB2Q37088533-57B72BFD-B1D4-451F-B03C-714A0FEDE144Q39761831-BBD54103-1607-421A-AD24-7BFF264CF5FDQ40134099-96469D7B-C9C7-4949-89BE-776F8F287808Q44971535-C1C2B67F-36BE-4F96-A15C-C4ED9903AC86Q48769242-65E28497-2DF8-49AC-83D1-35A4805B17A3
P2860
Is intravenous recombinant tissue plasminogen activator (rt-PA) safe for use in patients over 80 years old with acute ischaemic stroke? - The Calgary experience.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Is intravenous recombinant tis ...... oke? - The Calgary experience.
@ast
Is intravenous recombinant tis ...... oke? - The Calgary experience.
@en
type
label
Is intravenous recombinant tis ...... oke? - The Calgary experience.
@ast
Is intravenous recombinant tis ...... oke? - The Calgary experience.
@en
prefLabel
Is intravenous recombinant tis ...... oke? - The Calgary experience.
@ast
Is intravenous recombinant tis ...... oke? - The Calgary experience.
@en
P2093
P356
P1433
P1476
Is intravenous recombinant tis ...... oke? - The Calgary experience.
@en
P2093
Calgary Stroke Programme
David L Sandler
J H Warwick Pexman
Jessica E Simon
P304
P356
10.1093/AGEING/AFH031
P577
2004-03-01T00:00:00Z